Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
US-2024158357-A1 · May 16, 2024 · US
Substituted quinazolinones as vanilloid antagonists
US9102653B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9102653-B2 |
| Application number | US-201414322165-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 2, 2014 |
| Priority date | Jun 8, 2004 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating eye pain in a mammal, comprising: administering to a mammal in need thereof a therapeutically effective amount of a quinazolinone compound of the formula: in free base form or in pharmaceutically acceptable acid addition salt form.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9102653B2 cover?
- The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification C07D239/91. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).